OUR PURPOSE PIONEERING SCIENCE COMMUNITY REPORTING 81 ADVANCING HEALTHY CLIMATE, HEALTHY LIVES™ BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE ENVIRONMENT Developing sustainable products and packaging Last year, we made progress in developing Principles for Sustainable Drug Development, addressing Biogen’s multi-franchise portfolio with circular economy principles. Currently, we are working to build on a successful 2021 pilot of My Green Lab in which the 14 labs were awarded Green Lab Certification: four received Green (highest level), four Platinum and six Gold. This year, we expect approximately 65 lab groups to participate in total. We also are reviewing packaging solutions for our full product portfolio and conducting life cycle assessments (LCAs) to develop a roadmap toward more sustainable alternative materials for our legacy products. To advance these goals, we are developing collaborations with suppliers to increase the proportion of sustainable material in our packaging systems and the percentage of renewable energy to produce our packaging, from glass vials to cardboard. When it comes to our product packaging, we have many considerations, with the most important being focused on patients. We must ensure the packaging of our life-saving therapies maintains the safety and quality of the product while providing convenient access. We also are working to make our packaging more sustainable by reducing its life cycle impact. In balancing product quality, protection and access with environmental concerns around plastics, we have a hierarchy in considering plastic packaging adjustments: – Avoid plastic use, including replacing plastic where possible. – Reduce plastic use. – Reuse plastics, where we can do so safely. At the end of 2020, we developed a new concept of packaging design and material. The design was accepted in 2021 to support our Interferon packaging platform for autoinjector (Plegridy IM and Avonex Next Generation). The packaging system is based on the replacement of plastic material and bleached cardboard by a more sustainable molded fibers tray combined with a cardboard based on grass fibers and paper (variable percentage of recycled fibers), which provide better end-of-life options. The patient response to the packaging innovation implemented during the Human Factor study was overwhelmingly positive. We plan to apply that new concept of 100% recyclable and biodegradable material to the packaging of the interferon platform by 2021, reducing an estimated 80% of CO 2 -associated emissions. In 2022, we initiated the development of a new secondary packaging design based on the same platform approach. The plan is to propose this new design for ADUHELM®, TYSABRI® and our biosimilar products. Expanding our electric vehicle fleet We are transitioning our entire vehicle fleet to electric by 2025, with a goal of 100% battery electric vehicles (BEVs). We began with a pilot across the U.S. and European affiliates with adequate BEV availability and charging infrastructure. The program includes home charger installation with each vehicle, significant expansion of office charging Biogen is shifting to an electric vehicle fleet by 2025 as part of its target to become free of fossil fuels.